Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer
NCT03129698Phase 2Unknown
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03129698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129698.